CD274 and neoplasm: A broadly used metric to assess tumor immune microenvironment (TIME) and to predict tumor responsiveness to immune checkpoint immunotherapy (ICI) is immunohistochemistry analysis of programmed cell death ligand (PD-L1) expression.